Table 1.
Name of the compound | Mechanism of action | Phase of clinical trial development | Company |
---|---|---|---|
IDH1-vac | Activation of IDH1R132H-specific T cells | I | German Cancer Research Center, Heidelberg University |
PEPIDH1M | Activation of IDH1R132H-specific T cells | I | Duke University |
IDH1R132H-DC vaccine | Activation of IDH1R132H-specific T cells | I | Beijing Tiantan Hospital |
IDH, isocitrate dehydrogenase.